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Abstract
Background: We have recently completed an evaluation of the safety and feasibility of intravenous delivery of
autologous bone marrow in patients with progressive multiple sclerosis (MS). The possibility of repair was suggested by
improvement in the neurophysiological secondary outcome measure seen in all participants. The current study will
examine the efficacy of intravenous delivery of autologous marrow in progressive MS. Laboratory studies performed in
parallel with the clinical trial will further investigate the biology of bone marrow-derived stem cell infusion in MS,
including mechanisms underlying repair.
Methods/design: A prospective, randomised, double-blind, placebo-controlled, stepped wedge design will be employed
at a single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive
disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS). Participants will be randomised to
either early or late (1 year) intravenous infusion of autologous, unfractionated bone marrow. The placebo intervention is
infusion of autologous blood. The primary outcome measure is global evoked potential derived from multimodal evoked
potentials. Secondary outcome measures include adverse event reporting, clinical (EDSS and MSFC) and self-assessment
(MSIS-29) rating scales, optical coherence tomography (OCT) as well as brain and spine MRI. Participants will be followed
up for a further year following the final intervention. Outcomes will be analysed on an intention-to-treat basis.
Discussion: Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS) is the first
randomised, placebo-controlled trial of non-myeloablative autologous bone marrow-derived stem cell therapy in MS. It
will determine whether bone marrow cell therapy can, as was suggested by the phase I safety study, improve conduction
in multiple central nervous system pathways affected in progressive MS. Furthermore, laboratory studies performed in
parallel with the clinical trial will inform our understanding of the cellular pharmacodynamics of bone marrow infusion
in MS patients and the mechanisms underlying cell therapy.
Trial Registration: ISRCTN27232902 Registration date 11/09/2012. NCT01815632 Registration date 19/03/2013
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Background
Multiple sclerosis (MS) affects approximately 2.5 million
people worldwide. Although most patients present with
relapsing-remitting disease, over 80 % of patients
develop progressive disability. Although treatments to
reduce relapse frequency are available, very limited pro-
gress has been made in the prevention or reversal of
progressive disability. The development of cell therapy
to treat progressive MS is an attractive option due to
the multiplicity of actions that may be employed in-
cluding immunomodulatory, neuroprotective and rep-
arative processes.
We have recently completed a phase I safety and
feasibility study of intravenous autologous bone mar-
row (BM) infusion in patients with progressive MS
[1]. This study not only confirmed safety but also
raised the possibility of partial repair; conduction
times in multiple central nervous system (CNS) path-
ways collated as a composite score known as the glo-
bal evoked potential (GEP) [2, 3] improved in all
patients studied (n = 6) [1]. We believe that this re-
quires urgent investigation to determine if autologous
bone marrow infusion does indeed exert a genuine
reparative effect in progressive MS.
Methods
Objective and hypothesis
We hypothesise that intravenously delivered autolo-
gous bone marrow cell therapy (BMCT) in chronic
MS offers significant benefit. We further postulate that
the mechanisms are multiple, and include immunomodu-
lation and reparative and/or neuroprotective effects
within the CNS; and are offered by one or more BM stem
cell sub-populations, jointly contributing to the thera-
peutic impact. Exploring and understanding these mecha-
nisms, and the biology of the cells responsible, will allow
the development of more effective reparative cell therapy
in MS.
On this underlying hypothesis, we propose a phase II
controlled trial in parallel with a significant body of
translational and back-translational laboratory research,
with the following objectives:
1. To determine the efficacy of intravenous infusion of
autologous bone marrow cells in patients with
progressive MS
2. To collect additional safety data regarding the
collection and intravenous infusion of bone marrow
cells in those with MS
3. The laboratory arm of the study will explore the
mechanisms underlying the efficacy of infusion of
bone marrow cells in MS to determine how these
can be augmented and, potentially, how the need for
bone marrow harvest can be obviated.
Trial design
Assessment of bone marrow-derived Cellular Therapy in
progressive Multiple Sclerosis (ACTiMuS) is a double
blind, randomised, placebo-controlled single centre,
stepped wedge design trial [4] in adults with progressive
MS and Expanded Disability Status Scale (EDSS) score
4.0–6.0 (walking affected by disease, but still able to
walk, with aids if necessary; distance as determined by
the Ambulation Score). The study schema is presented
in Fig. 1.
Sample size estimation
We will randomly allocate 40 patients, 30 with secondary
progressive disease (SPMS) and 10 with primary progres-
sive disease (PPMS), to each arm of the study, allowing a
difference of between 0.63 and 0.73 of a standardised
difference in GEP between the arms to be detected with
80 % power at the 5 % significance level, assuming a loss
to follow-up rate of between 0 and 25 % respectively. Our
Fig. 1 Study schema for the ACTiMuS trial
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experience suggests that, given the close involvement of
patients and staff, we will achieve around 95 % follow-up.
Eligibility and enrolment
Participants will be patients attending the Bristol and
Avon Multiple Sclerosis (BrAMS) Unit, North Bristol
NHS Trust, UK. To enter the study, participants will have
progressive MS and will have given informed consent. In
addition, they must fulfil the inclusion and exclusion
criteria as detailed in Table 1.
Randomisation and blinding
Randomisation will be centrally allocated using the infra-
structural facilities of the Bristol Randomised Trials Collab-
oration (Departments of Social and Community Medicine),
which provides web-based automatic randomisation ser-
vices. Randomisation will be stratified by disease type
(PPMS versus SPMS) using a permuted block design to en-
sure balance of allocation to the immediate or delayed
treatment groups. Allocations are only released once the
new study participant is logged into the system, thus ensur-
ing allocation concealment. The results of randomisation
will be held by NHS Blood and Transplant (NHSBT) and
will be released only when the trial is to be unblinded and
at the request of the Trial Management Committee.
During infusion, the trial product (blood or marrow)
will be shielded from the participants using covered
giving sets and obscuring the cannula site from the par-
ticipant. Trial assessors do not have access to informa-
tion regarding the order in which blood and marrow are
infused. The level of unmasking of participants, treating
physicians and assessors will be assessed by direct ques-
tioning at the end of the study.
Trial interventions
Venesection
Venesection of approximately 500 mL will be performed
at entry and at 1 year. Blood donation will be performed
in accordance with NHS Blood and Transplant standard
operating procedures which comply with UK guidelines
[5]. Briefly, a cannula is inserted in the antecubital fossa
and venesection is performed with a sphygmomanom-
eter cuff inflated to 60 mmHg.
Bone marrow harvest and infusion
Bone marrow harvest will be performed under general
anaesthesia. Approximately 500–600 mL marrow will be
Table 1 Eligibility criteria for the ACTiMuS trial
Inclusion criteria Exclusion criteria
Either sex, 18–65 years old Pregnancy, breastfeeding or lactation
Diagnosis of clinically definite MS as defined
by the McDonald criteria
History of autologous/allogeneic bone marrow transplantation
or peripheral blood stem cell transplant
Bone marrow insufficiencyMS disease severity EDSS 4–6
History of lymphoproliferative disease or previous total lymphoid irradiation
Immune deficiency
Disease duration >5 years
History of current or recent (<5 years) malignancy
Disease progression (not attributable to relapse)
in the year prior to entry
Chronic or frequent drug-resistant bacterial infections or presence of
active infection requiring antimicrobial treatment
Signed, written informed consent
Frequent and/or serious viral infection
Willing and able to comply with study visits
according to protocol for the full study period
Systemic or invasive fungal disease within 2 years of entry to study
Significant renal, hepatic, cardiac or respiratory dysfunction
Contraindication to anaesthesia
Bleeding or clotting diathesis
Current or recent (within preceding 12 months) immunomodulatory
therapy other than corticosteroid therapy
Treatment with corticosteroids within the preceding 3 months
Significant relapse within preceding 6 months
Predominantly relapsing-remitting disease over preceding 12 months
Radiation exposure in the past year other than chest/dental x-rays
Previous claustrophobia
The presence of any implanted metal or other contraindication to MRI
Participation in another experimental study or treatment within previous
24 months
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collected together with bone marrow trephine. The mar-
row aspirate will be filtered, bagged and labelled by
NHSBT. An infusion of either blood or marrow will
be performed on the day of bone marrow harvest.
Analgaesia will be offered and a check FBC will be
performed. Iron replacement therapy will be given if
Hb <9.5 g/dL pre-harvest or Hb <7.5 g/dL post-
harvest (ferrous sulphate 200 mg od for 1 month). One
year later, intravenous infusion of blood or thawed mar-
row will be performed (whichever was not infused at the
time of harvest).
Bone marrow trephines and a small sample of the
bone marrow aspirate will be retained for back-
translational laboratory research studies running in
parallel with the clinical trial if specific written in-
formed consent is given. Blood samples for research
purposes may be requested throughout the duration
of the study.
Outcome measures
Primary outcome measure
Multimodal evoked potentials will be examined at 0, 6,
12, 18 and 24 months. Evoked potential abnormalities will
be quantified according to a 4-point graded ordinal score
modified from Leocani et al. (0 = normal; 1 = increased
latency; 2 = increased latency and abnormal amplitude;
3 = absent) [3]. The primary outcome measure is change
in GEP in the 12-month period after infusion of autolo-
gous marrow.
The recording of the evoked potentials shall be in
accordance with the Guidelines of the International Feder-
ation of Clinical Neurophysiology [6], and analysis will be
performed using standard methods [7] (Table 2). Electro-
physiological responses shall be considered abnormal if
they exceed 2.5 standard deviations of the normal values
or cannot be detected.
Secondary outcome measures
Adverse events (AEs), serious adverse events (SAEs),
safety tests, clinical measures of disability, optical co-
herence topography (OCT) and magnetic resonance
imaging (MRI) findings are included as secondary
outcome measures.
Adverse events
Any unfavourable and unintended sign, symptom or
illness that develops or worsens during the period of
the study is classified as an AE, whether or not it is
considered to be related to study interventions. Ad-
verse events include unwanted side effects, toxicity or
sensitivity reactions, abnormal laboratory results and
injury or intercurrent illnesses, and may be expected
or unexpected.
Furthermore, if an adverse event:
 results in death
 is life threatening
 requires hospitalisation or prolongation of existing
hospitalisation
 results in persistent or significant disability or
incapacity
 consists of a congenital anomaly or birth defect
 or is considered by the investigator to be an
important medical event,
then it is classified as an SAE and must be reported to
the trial coordinating centre as soon as possible.
It is expected that some participants will be hospitalised
during the study for MS-related problems. These events
should be classified as SAEs and reported accordingly.
However, a hospital admission for a procedure planned be-
fore entry into the study will not be recorded as an SAE.
Expected adverse events include:
 Local bruising and discomfort following bone
marrow harvest
 Increase in lower limb spasticity following bone
marrow harvest
 Acute urinary retention following bone marrow
harvest
 Temporary exacerbation of MS following general
anaesthesia
 Hypovolaemia or anaemia following blood and
marrow donation
 Hypersensitivity to marrow cryopreservative
 Exacerbation of MS due to sepsis, for example,
urinary tract infection or chest infection
 Assessment at or admission to hospital following fall
Table 2 Method for recording of multimodal evoked potentials
Visual evoked potentials (VEPs) will be evoked with a rear-projected
checkerboard pattern using an opto-mechanical device subtending 30
degrees at the retina, check-size 1 degree, white brightness of 150cdm−2
and contrast 87.5 %.
Monaural stimulation will be delivered via earphones to each side with
rarefaction click stimuli of 0.1 ms duration at an intensity of 75 dB above
the subjective hearing threshold whilst the contralateral ear is masked
with white noise.
Sensory evoked potentials (SEPs) will be obtained by delivering electrical
stimulation with square wave pulses of 0.2 ms duration to the median
and the posterior tibial nerves, at the wrist and ankle respectively.
Motor evoked potentials (MEPs) will be recorded from electrodes
situated over the abductor pollicis brevis muscle in the hand and the
abductor hallucis in the foot using a 9 cm circular coil held over the
vertex. The central motor conduction time (CMCT) will be calculated by
subtracting ½(M + F + 1) from the MEP latency where M is the distal
motor latency and F is the minimum F wave latency.
The GEP score will then be calculated as the sum of left and right
brainstem auditory evoked potential (BSAEP) and VEP scores (0–12) and
left and right upper and lower SEPs (0–12) and CMCTs (0–12).
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Clinical laboratory tests for safety analyses
Blood taken for safety analyses will be screened as
follows: urea and electrolytes, liver function tests, full
blood count with differential white cell count, coagulation,
group and save, C-reactive protein, glucose, calcium, mag-
nesium, chloride, bicarbonate, phosphate, viral serology
(including cytomegalovirus, Epstein-Barr virus, herpes
simplex virus, varicella zoster virus, toxoplasmosis, hepa-
titis B and C, human immunodeficiency virus, human T
cell lymphoma virus and syphilis screening. Urinalysis
(microscopy and culture) will also be performed.
Clinical outcome measures
Clinical outcomes will be assessed at entry and after
each intervention at 6 weeks, 6 months and 1 year. The
clinical rating scales will include the widely used
Expanded Disability Status Scale (EDSS) [8] together
with the Multiple Sclerosis Functional Composite (MSFC).
The latter is a three-part quantitative assessment including
a timed walk, nine-hole peg test and Paced Auditory Serial
Addition Test (PASAT) [9]. In addition, participants will be
asked to complete the MS Impact Scale (MSIS-29), which
is a well-validated patient-completed rating scale [10–13].
Paraclinical outcome measures
Magnetic resonance imaging (MRI) Participants will
undergo cranial and spinal MRI at three time points: at
baseline and at the end of years 1 and 2. The secondary
MRI outcome measures will relate to 1) lesion load, 2)
atrophy measures both of the brain and of cross-
sectional area of the spinal cord [14], and (3) changes in
mean diffusivity [15].
Exploratory analysis of the resting-state fMRI data will
investigate correlations between network patterns and
‘strength’ of networks connectivity from the resting-state
fMRI with classifications revealed by the various evoked
potential studies [16–18].
Optical coherence tomography (OCT) Measurement
of retinal nerve fibre layer thickness [19] and macular
volume [20] using OCT is increasingly recognized as an
objective outcome measure which accurately reflects
axonal loss.
The measures taken for secondary outcomes are as
follows:
1. Safety: evaluation of number and nature of adverse
events
2. Physician-based EDSS: time to EDSS progression
of at least one point from a baseline EDSS of 4.0,
4.5 or 5.0 or at least 0.5 point from a baseline
EDSS ≥5.5.
3. Patient-based MSIS-29 physical impact scale version
2: overall mean change from baseline to end of study
4. MSFC: overall mean change of z-scores, from baseline
to final visit
5. MRI head: T1 weighted 3D gradient echo, 3D
FLAIR, DTI and MRI cord (3D gradient echo)
6. OCT: macular volume, thickness of retinal cell layer
7. Annual overall patient and treating physician
assessments of efficacy.
Trial analyses
A full statistical analysis plan will be written prior to
completion of data collection and analyses. The null hy-
pothesis is that there will be no significant difference in
the primary and secondary outcomes between interven-
tion and control arms at (a) 12 months, and (b) 2 years.
The first 12 months will be a standard comparison of
the intervention against control (hypothesis a), while the
assessment at 2 years will be a comparison between im-
mediate versus delayed treatment (hypothesis b). We will
also have a 2 years’ follow-up and be able to look at the
longer term effects of the intervention in patients receiv-
ing it immediately.
The distribution of GEPs will be examined and, based
on the prior work by Leocani and colleagues [3], it is
likely that this will be relatively normally distributed or
slightly skewed. In this case we will use conventional lin-
ear regression models to estimate the differences in
mean GEP between study arms, with 95 % confidence
intervals and P-values, to address the above hypotheses
(a) and (b) in turn, adjusting for covariates, including
baseline GEP and disease type. These primary analyses
will follow the intention-to-treat principle.
In addition, a secondary analysis of the measures of
GEP at 0, 6, 12, 18 and 24 months will investigate the
effect of the intervention over time. This investigation is
likely to use a random effects analysis, to allow for individ-
ual variation in the level of and degree of change in GEP.
Our pre-specified sub-group analyses will compare the
magnitude of the treatment effect on GEP between sub-
groups defined by gender, baseline GEP and disease type.
Analysis of secondary outcomes will be clearly delin-
eated from the primary analysis in any statistical reports
produced. Secondary outcomes (MSFC, category rating
scales, annual overall patient and treating physician as-
sessments of efficacy) will be scored according to standard
methodology and analysed in a similar way to the primary
outcome. Conventional linear regression models will be
used for continuous secondary outcome measures, and
logistic regression or related methods for binary and cat-
egorical outcome measures.
Imaging results will be analysed using a multi-level
model enabling accommodation of missing data. The
incidence rates of AEs and SAEs will be summarised
by treatment group. The proportion of participants
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discontinuing treatment will be summarised by reason
and by treatment group.
Secondary analysis of EDSS
The analysis of EDSS will follow the established practice of
using time to first progression as the primary endpoint.
However, this approach is not optimal in terms of statistical
power, and we will be collecting data on disease progression
for the full follow-up duration of the trial allowing an ana-
lysis based on mean scores over the follow-up period.
Exploratory analyses
Exploratory analyses will be clearly delineated from the
analysis of primary and secondary outcomes in any stat-
istical reports. The exploratory analysis will include
prognostic and predictive factor analysis of disease pro-
gression and multivariate analysis of response data.
Ethical considerations
The ACTiMuS trial will be undertaken in compliance
with the World Medical Association Declaration of
Helskinki (revised version of Seoul, 2008) and inter-
national standards of Good Clinical Practice. Trial de-
sign and processes for implementation have the approval
of the UK National Research Ethics Committee (NRES
Committee South West – Frenchay, 12SW0358).
Discussion
Our phase I study established the feasibility of autolo-
gous bone marrow infusion in patients with MS, pro-
vided good evidence of safety and offered preliminary
suggestions of efficacy [1]. ACTiMuS will determine
whether infusion of autologous marrow does indeed lead
to improvements in CNS conduction in patients with
progressive MS.
Our proposed trial utilises a randomised, blinded,
immediate-versus-delayed therapy controlled protocol.
There are two reasons for this design. Firstly, to main-
tain blinding all patients must believe they could be re-
ceiving active intervention, and so all must undergo
marrow harvesting. It then becomes unreasonable (and
arguably unacceptable) for participants not to receive
therapy. This tension is resolved by treating all subjects,
but establishing a control arm by comparing immediate
versus delayed administration using the stepped wedge
design. Secondly, there is very limited evidence as to
whether any benefit associated with BM stem cells re-
mains constant, declines or even improves over time. By
comparing immediate with delayed therapy we can test
whether an additional year of follow-up is associated
with any differences in outcomes.
The difficulties of demonstrating neuroprotective or
reparative effects over relative short periods of time in
progressive MS have been well documented [21]. The
GEP has been developed as a tool that, by combining
multimodal evoked potential recordings to a single
score, may be used to monitor the evolution of MS in
individual patients. It has also been employed as a surro-
gate endpoint in clinical trials, and longitudinal studies
in significant numbers of patients with MS (>80) have
validated the GEP as a marker of the severity of CNS
damage and its progression [3, 22]. Our phase I study
helped support the view that electrophysiological assess-
ment represents a sensitive and objective surrogate ap-
proach to exploring possible improvement in patients
with chronic disability in MS [1] and, combined with the
supportive evidence outlined above, justifies our inclu-
sion of change in GEP as the primary outcome measure.
In our phase I trial, we elected to use a filtered prepar-
ation of whole bone marrow, rather than one or other
selected, growth factor-expanded sub-populations, for
several reasons. First, this mimicked the relatively unse-
lected mononuclear cell population that proved beneficial
in the first therapeutic studies in rodent demyelinating
models [23, 24]. Using unselected BM cells is an increas-
ingly common approach, successfully explored not just in
experimental models of stroke [25] and spinal cord injury
[26], but also clinically, in patients with myocardial infarc-
tion [27, 28], liver disease [29] and peripheral vascular
disease [30], and most recently stroke [31].
All BM stem cell sub-populations are in this way in-
cluded, and several may be beneficial. Multipotent mesen-
chymal stromal cells (MSCs) are important [32, 33], but
CD34-positive haematopoetic stem cells also have repara-
tive potential [34, 35], as do CD133-positive stem cells
[36, 37]; other less well-defined sub-populations including
Stro-1 positive cells [38–42] may also be valuable [43–45].
Cell selection obviously excludes the majority of cell types;
but the available evidence suggests that there is no reason
to exclude any specific BM stem cell sub-population;
indeed in some circumstances, unfiltered cells have better
reparative potential than MSCs [46].
Additionally, the repeated cell cycling and expansion to
prepare purified selected MSCs (or other sub-populations)
not only induces unwelcome genetic instability [47–49],
but may compromise differentiation and repair capacities
[50–54]. Finally, if there were benefit from non-selected,
non-expanded cells, it would be far easier (and cheaper) to
adopt and apply such therapies in relatively non-specialist
units, with no requirement for a sterile good manufacturing
practice (GMP) cell growth or selection facility.
This ’lumping not splitting’ approach creates the diffi-
culty of obscuring which cell sub-population(s) may actu-
ally contribute to the therapeutic effects, but these
questions are important opportunities rather than prob-
lems: exploring and dissecting the cells and mechanisms
relevant to the therapeutic effects should create significant
opportunities for developing, refining and improving this
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form of cell therapy in MS, and we will explore these
topics in the laboratory arm of the study which will run
concurrently with the clinical trial.
ACTiMuS is the first randomised clinical trial of unfrac-
tionated bone marrow-derived cell therapy (without
myeloablation) in MS and, as such, represents a landmark
in the development of reparative therapies for progressive
MS. Furthermore, it will test the sensitivity of employing a
modified cross-over protocol with GEP as the primary
outcome measure in progressive MS, with potential impli-
cation for future clinical trials of reparative and neuropro-
tective therapies in MS.
Trial status
Recruitment to the ACTiMuS trial commenced in
March 2014 and is ongoing.
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